Oncología Traslacional

Artículos Científicos

• Areses Manrique MC, Mosquera Martínez J, García González J, Afonso Afonso FJ, Lázaro Quintela M, Fernández Núnez N, Azpitarte Raposeiras C, Amenedo Gancedo M, Santomé Couto L, García Campelo MR, Munoz Iglesias J, Cortegoso Mosquera A, Vilchez Simo R, Casal Rubio J, Campos Balea B, Carou Frieiro I, Alonso-Jaudenes Curbera G, Anido Herranz U, García Mata J, Fírvida Pérez JL. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl Lung Cancer Res. 2018 Jun;7(3):404-415. doi: 10.21037/tlcr.2018.04.03. PubMed PMID: 30050778; PubMed Central PMCID: PMC6037977. +Pubmed
• Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, Climent MÁ, Olmos D, Carles J, Lázaro M. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):57-68. PMID: 29134562. http://www.ncbi.nlm.nih.gov/pubmed/29134562 +Pubmed +DOI
• Costa Rivas M, Huidobro Vence G, Fírvida Pérez JL, Campos Balea B, García Gonzalez J, Lázaro Quintela M, Caeiro Munoz M, Taboada Valladares B, Castro Gómez JE, Vázquez Estevez S, Afonso Afonso FJ, Azpitarte Raposeiras C, Amenedo Gancedo M, Casal Rubio J. Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group. Clin Transl Oncol. 2018 Nov;20(11):1467-1473. doi: 10.1007/s12094-018-1880-x. Epub 2018 Apr 25. PubMed PMID: 29696478. +Pubmed
• Costa Rivas M, Huidobro Vence G, Fírvida Pérez JL, Campos Balea B, García Gonzalez J, Lázaro Quintela M, Caeiro Munoz M, Taboada Valladares B, Castro Gómez JE, Vázquez Estevez S, Afonso Afonso FJ, Azpitarte Raposeiras C, Amenedo Gancedo M, Casal Rubio J. Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group. Clin Transl Oncol. 2018 Apr;(E-PUB) PMID: 29696478. http://www.ncbi.nlm.nih.gov/pubmed/29696478 +Pubmed +DOI
• Fernández A, Salgado M, García A, Buxo E, Vera R, Adeva J, Jiménez-Fonseca P, Quintero G, Llorca C, Canabate M, López LJ, Munoz A, Ramírez P, González P, López C, Reboredo M, Gallardo E, Sanchez-Cánovas M, Gallego J, Guillén C, Ruiz-Miravet N, Navarro-Pérez V, De la Cámara J, Alés-Díaz I, Pazo-Cid RA, Carmona-Bayonas A. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. BMC Cancer. 2018 Nov 29;18(1):1185. doi: 10.1186/s12885-018-5101-3. PubMed PMID: 30497432; PubMed Central PMCID: PMC6267080. +Pubmed
• Fernández Montes A, Martínez Lago N, Covela Rúa M, de la Cámara Gómez J, González Villaroel P, Méndez Méndez JC, Jorge Fernández M, Salgado Fernández M, Reboredo López M, Quintero Aldana G, Luz Pellón Augusto M, Grana Suárez B, García Gómez J. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. Cancer Med. 2019 Mar;8(3):882-889. doi: 10.1002/cam4.1903. Epub 2019 Jan 28. PubMed PMID: 30690930; PubMed Central PMCID: PMC6434192. +Pubmed
• Losa F, Soler G, Casado A, Estival A, Fernández I, Giménez S, Longo F, Pazo-Cid R, Salgado J, Seguí MÁ. SEOM clinical guideline on unknown primary cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):89-96. PMID: 29230692. http://www.ncbi.nlm.nih.gov/pubmed/29230692 +Pubmed +DOI
• Paumard-Hernández B, Calvete O, Inglada Pérez L, Tejero H, Al-Shahrour F, Pita G, Barroso A, Trivino JC, Urioste M, Valverde C, González Billalabeitia E, Quiroga V, Rodríguez Moreno JF, Fernández Aramburo A, López C, Maroto P, Sastre J, Juan Fita MJ, Duran I, Lorenzo-Lorenzo I, Iranzo P, García Del Muro X, Ros S, Zambrana F, Autran AM, Benítez J. Whole Exome Sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer. Int J cancer. 2018 May;(E-PUB):1-30. PMID: 29761480. http://www.ncbi.nlm.nih.gov/pubmed/29761480 +Pubmed +DOI
• Sabell Pérez-Salgado F, Vázquez-Estévez S, Anido-Herranz U, Blanco-Parra M, Casas-Nebra FJ, Fernández-Calvo O, Lázaro-Quintela M, López-García S. Approach of the patient with renal cancer: Is there a collaboration between urology and oncology? Actas Urol Esp. 2018 Jan – Feb;42(1):1-4. doi: 10.1016/j.acuro.2017.04.001. Epub 2017 Jun 3. English, Spanish. PubMed PMID: 28587846. +Pubmed

Artículos Científicos

• Areses M, Campelo RG, García González J, Afonso FJ, Lazaro ME, Campos B, Azpitarte C, Amenedo M, Santomé L, Ron DA, Alonso-Jaudenes G, Baron F, Vilchez R, Casal J, Fernandez N, Carou I, Mosquera J, Anido U, Garcia Mata J, Firvida J. The real-world experience with nivolumab in previously treated patients with advanced non small cell lung cancer (NSCLC): A Galician Lung Cancer Group clinical practice. J Clin Oncol. 2017 May;35(15_suppl):e20564. DOI: 10.1200/JCO.2017.35.15_suppl.e20564. IF2017: 26.360; D1. http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.e20564 +DOI
• Barnes TA, Amir E, Templeton AJ, Gomez-Garcia S, Navarro B, Seruga B, Ocana A. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treat Rev. 2017 May;56:1-7. PMID: 28437678. IF2017: 8.122; D1. http://www.ncbi.nlm.nih.gov/pubmed/28437678 +Pubmed +DOI
• Cameselle-Teijeiro JF, Valdés-Pons J, Cameselle-Cortizo L, Fernández-Pérez I, Lamas-González MJ, Iglesias-Faustino S, Alonso-Figueirido E, Cortizo-Torres M-E, Agras-Suárez M-C, Iglesias-Salgado A, Salgado-Costas M, Friande-Pereira S, Schmitt FC. Tumours of the Uterine Corpus: A Histopathological and Prognostic Evaluation Preliminary of 429 Patients. J Clin Med Exp Images. 2017;1(1):011-9. DOI: 10.29328/journal.jcmei.1001004. IF2017: N/A. https://www.heighpubs.org/jcmei/jcmei-aid1004.php +DOI
• De Castro J, González-Larriba JL, Vázquez S, Massutí B, Sanchez-Torres JM, Dómine M, Garrido P, Calles A, Artal A, Collado R, García R, Sereno M, Majem M, Macías JA, Juan O, Gómez-Codina J, Hernández B, Lázaro M, Ortega AL, Cobo M, Trigo JM, Carcereny E, Rolfo C, Macia S, Munoz J, Diz P, Méndez M, Rosillo F, Paz-Ares L, Cardona J V, Isla D. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. Clin Transl Oncol. 2017 Feb;19(2):219-26. PMID: 27371031. IF2017: 2.392; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27371031 +Pubmed +DOI
• Gomez Garcia S, Costa Rivas M, Areses Manrique MC, Fernández Núnez N, Garcia J, Caeiro M, Castro E, Formoso I, Calvo P, De Dios Alvarez N, Firvida J, Campos B, Azpitarte C, Afonso FJ, Amenedo M, Casal Rubio J. Concurrent chemoradiation (CChRT) for locally advanced stage III non-small cell lung cancer (NSCLC) with cisplatin and vinorelbine and thoracic radiotherapy: A phase II study from the Galician Lung Cancer Group. J Clin Oncol. 2017 May;35(15_suppl):e20067. DOI: 10.1200/JCO.2017.35.15_suppl.e20067. IF2017: 26.360; D1. http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.e20067 +DOI
• González Del Alba A, Arranz JÁ, Puente J, Méndez-Vidal MJ, Gallardo E, Grande E, Pérez-Valderrama B, González-Billalabeitia E, Lázaro-Quintela M, Pinto Á, Lainez N, Piulats JM, Esteban E, Maroto Rey JP, García JA, Suárez C. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. Crit Rev Oncol Hematol. 2017 May;113:171-90. PMID: 28427506. IF2017: 4.495; Q1. http://www.ncbi.nlm.nih.gov/pubmed/28427506 +Pubmed +DOI
• González-Larriba JL, Lázaro-Quintela M, Cobo M, Dómine M, Majem M, García-Campelo R. Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis. Transl lung cancer Res. 2017 Dec;6(Suppl 1):S21-34. PMID: 29299405. IF2017: N/A. http://www.ncbi.nlm.nih.gov/pubmed/29299405 +Pubmed +DOI
• Lorenzo-Lorenzo I, Fernández-Pérez I, Alonso-Herrero A, Villanueva-Sil MJ. Breast Cancer Chemoprevention: What and When? Cancer Chemother Rev. 2017;12(2):46-57. IF2017: N/A. http://www.cancerchemotherapyreviews.com/resumen.asp?id=860&indice=2017122
• Martin Jimenez M, Calvo Ferrandiz A, Aparicio Urtasun J, Garcia-Campelo R, Gonzalez-Flores E, Lazaro Quintela M, Munoz Mateu M, Rodriguez Sanchez CA, Santaballa Bertran A, Sepulveda Sanchez JM, Vera Garcia R, Virizuela Echaburu JA, Segui Palmer MA. New clinical trials regulation in Spain: analysis of royal decree 1090/2015. Clin Transl Oncol. 2017 Mar;19(3):291-300. PMID: 27718157. IF2017: 2.392; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27718157 +Pubmed +DOI
• Méndez Méndez JC, Ramos M, De la Cámara Gómez JC, Pellón ML, Covela M, Quintero Aldana GA, Salgado Fernandez M, Fernández-Montes A, Reboredo M, Valladares-Ayerbes M, Jorge Fernandez M, González Villarroel P, Romero Reinoso C. 553P – First-line panitumumab (P) plus capecitabine (C) for the treatment of elderly patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): Preliminary results of the phase II, PANEL GITuD-2011-01 study. Ann Oncol. 2017 Sep;28(suppl_5):553P. DOI: 10.1093/annonc/mdx393.079. IF2017: 13.930; D1. http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx393.079/4109851/553PFirstline-panitumumab-P-plus-capecitabine-C +DOI
• Ocana Fernandez A, Ruiz Borrego M, Gil Martin M, Antolin S, Atienza M, Montano A, Ribelles N, Guerrero A, Munoz M, Fernández-Pérez I, Urruticoechea A, Falcon Gonzalez A, Pernas Simon S, Prato Varela J, Escudero MJ, Benito S, Caballero R, Carrasco E, Rojo F, Pandiella A. 239PD – A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04. Ann Oncol. 2017 Sep;28(suppl_5):239PD. DOI: 10.1093/annonc/mdx365.002. IF2017: 13.930; D1; JCR-CAT: ONCOLOGY. http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx365.002/4108468/239PDA-phase-II-trial-of-dasatinib-D-in +DOI
• Perez-Segura P, Palacio JE, Vazquez L, Monereo S, de Las Penas R, de Icaya PMM, Gravalos C, Lecube A, Blasco A, Garcia-Almeida JM, Barneto I, Goday A, Pérez-Segura P, Palacio JE, Vázquez L, Monereo S, de Las Penas R, de Icaya PMM, Grávalos C, Lecube A, Blasco A, García-Almeida JM, Barneto I, Goday A. Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2017 Jun;19(6):682-94. PMID: 28074400. IF2017: 2.392; Q3. http://www.ncbi.nlm.nih.gov/pubmed/28074400 +Pubmed +DOI
• Sabell Pérez-Salgado F, Vázquez-Estévez S, Anido-Herranz U, Blanco-Parra M, Casas-Nebra FJ, Fernández-Calvo O, Lázaro-Quintela M, López-García S. Approach of the patient with renal cancer: Is there a collaboration between urology and oncology? Actas Urol Esp. 2017 Jun;42(1):1-4. PMID: 28587846. IF2017: 1.260; Q4. http://www.ncbi.nlm.nih.gov/pubmed/28587846 +Pubmed +DOI
• Vera R, Gómez M, Ayuso JR, Figueras J, Garcia-Alfonso P, Martinez V, Lacasta A, Ruiz A, Safont MJ, Aparicio J, Campos J, Cámara J, Martin M, Montagut C, Pericay C, Viéitez JM, Falcó E, Jorge M, Marín Vera M, Salgado Fernandez M. 590P – Correlation between RECIST-criteria, morphologic response by CT and pathologic regression in hepatic metastasis secondary to colorectal cancer: The AVAMET study. Ann Oncol. 2017 Sep;28(suppl_5):590P. DOI: 10.1093/annonc/mdx393.115. IF2017: 13.930; D1. http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx393.115/4109887/590PCorrelation-between-RECISTcriteria-morphologic +DOI

Guías de Práctica Clínica

• Álvarez López J, Fernández-Calvo O, Charín Pato G. Fisterra Guías Clínicas: Melanoma cutáneo. 2017. +Info https://www.fisterra.com/guias-clinicas/melanoma-cutaneo/#27021
• Fernández-Pérez I, Alonso-Herrero A, Gómez-García S, Costa-Rivas M. Enfermedad Tromboembólica Venosa y Cáncer de Ovario. Oncology Thrombosis Risk. Esmon Publicidad; 2017. ISBN: 9788494660511. +Info https://books.google.es/books/about/Enfermedad_tromboembólica_venosa_y_cán.html?id=UwrNwQEACAAJ&redir_esc=y
• Fírvida-Pérez JL, Arias-Ron D, Fernández-Calvo O. Fisterra Guías Clínicas: Cáncer de pulmón. 2017. +Info https://www.fisterra.com/guias-clinicas/cancer-pulmon/#26990
• Lamelo-Alfonsín F, Charlín-Pato G, Fernandez-Calvo O. Fisterra Guías Clínicas: Efectos secundarios del tratamiento oncológico. 2017. +Info https://www.fisterra.com/guias-clinicas/efectos-secundarios-tratamiento-oncologico/#26976

Artículos Científicos

• Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernández-Pérez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villa S. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol. 2016 May;127(3):569-79. PMID: 26847813. IF2016: 2.980; Q2. http://www.ncbi.nlm.nih.gov/pubmed/26847813 +Pubmed +DOI
• Cameselle-Teijeiro JF, Cameselle-Cortizo L, Valdés-Pons J, Fernández-Pérez I, Lamas-González M, Iglesias-Faustino S, Figueiredo-Alonso E, Cortizo-Torres M, Iglesias-Salgado A, Salgado-Costas M, Schmitt F. Breast Cancer and Ovarian Cancer in Monozygotic Twins. Clin Oncol. 2016;1:1016. IF2016: N/A. https://adicam.net/files/DOC-20160729-WA0012.pdf
• Estévez SV, Herranz UA, Calvo OF, Afonso Afonso FJ, Couto LS, Lázaro-Quintela M, Mateos LL, Maciá Escalante S. Prostate cancer perspectives after chaarted: Optimizing treatment sequence. Crit Rev Oncol Hematol. Elsevier Ireland Ltd; 2016 Nov;107:119-27. PMID: 27823639. IF2016: 4.491; Q1. http://www.ncbi.nlm.nih.gov/pubmed/27823639 +Pubmed +DOI
• Fonseca PJ, Carmona-Bayonas A, García IM, Marcos R, Castanón E, Antonio M, Font C, Biosca M, Blasco A, Lozano R, Ramchandani A, Beato C, de Castro EM, Espinosa J, Martínez-García J, Ghanem I, Cubero JH, Manrique IA, Navalón FG, Sevillano E, Manzano A, Virizuela J, Garrido M, Mondéjar R, Arcusa MÁ, Bonilla Y, Pérez Q, Gallardo E, del Carmen Soriano M, Cardona M, Lasheras FS, Cruz JJ, Ayala F, Spanish Soc Med Oncology SEOM, FINITE Investigators. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. Br J Cancer. 2016 May;114(11):1191-8. PMID: 27187687. IF2016: 6.176; Q1. http://www.ncbi.nlm.nih.gov/pubmed/27187687 +Pubmed +DOI
• García J, Santomé L, Anido U, Fernández-Calvo O, Afonso-Afonso J, Lázaro M, Medina A, Vázquez Estévez S. Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU). Curr Oncol Rep. 2016 Dec;18(12):72. PMID: 27812861. IF2016: 2.608; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27812861 +Pubmed +DOI
• Gómez García S, Clemons M, Amir E. Rethinking end-points for bone-targeted therapy in advanced cancer. Eur J Cancer. 2016 Aug;63:105-9. PMID: 27299662. IF2016: 6.029; Q1. http://www.ncbi.nlm.nih.gov/pubmed/27299662 +Pubmed +DOI
• Lainez N, García-Donas J, Esteban E, Puente J, Sáez MI, Gallardo E, Pinto-Marín Á, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Duran MA, Lázaro-Quintela M, González Del Alba A, Méndez-Vidal MJ, Chirivella I, Afonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnáiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Fernández Parra E, Villa Guzmán JC, Martínez-Ortega E, Belén González M, Morán M, Suarez-Paniagua B, Lecumberri MJ, Castellano D. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. BMC Cancer. 2016 Feb;16(1):135. PMID: 26906039. IF2016: 3.288; Q2. http://www.ncbi.nlm.nih.gov/pubmed/26906039 +Pubmed +DOI
• Lázaro M, Gallardo E, Doménech M, Pinto Á, Del Alba AG, Puente J, Fernández O, Font A, Lainez N, Vázquez S. SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016). Clin Transl Oncol. 2016 Dec;18(12):1197-205. PMID: 27900539. IF2016: 2.353; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27900539 +Pubmed +DOI
• López-Pousa A, Martin Broto J, Martinez Trufero J, Sevilla I, Valverde C, Alvarez R, Carrasco Alvarez JA, Cruz Jurado J, Hindi N, Garcia Del Muro X. SEOM Clinical Guideline of management of soft-tissue sarcoma (2016). Clin Transl Oncol. 2016 Dec;18(12):1213-20. PMID: 27905051. IF2016: 2.353; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27905051 +Pubmed +DOI
• Martínez-Janez N, Chacón I, de Juan A, Cruz-Merino L, Del Barco S, Fernández I, García-Teijido P, Gómez-Bernal A, Plazaola A, Ponce J, Servitja S, Zamora P. Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel. Breast Care (Basel). 2016 Apr;11(2):133-8. PMID: 27239176. IF2016: 1.553; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27239176 +Pubmed +DOI
• Pena C, Alvarez M, Fernández Núnez N, Alonso Herrero A, Amenedo M, Firvida Perez JL, Campos Balea BÂ, Gomez Garcia S, Covela Rúa M, Costa Rivas M, Cadavid Vieitez L, Vazquez-Estevez S. ERCC1 expression in tumor tissue as biomarker of outcomes of oral vinorelbine-cisplatin (oVP) combination in metastatic squamous cell lung cancer (SqLC): A prospective study-GGCP 052/12. J Clin Oncol. 2016 May;34(15_suppl):e20533. DOI: 10.1200/JCO.2016.34.15_suppl.e20533. http://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.e20533 +DOI
• Pérez-Segura P, Manneh R, Ceballos I, García A, Benavides M, Fuster J, Vaz MA, Cano JM, Berros JP, Covela M, Moreno V, Quintanar T, García Bueno JM, Fernández I, Sepúlveda J. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status. Clin Transl Oncol. 2016 Aug;18(8):805-12. PMID: 26542177. IF2016: 2.353; Q3. http://www.ncbi.nlm.nih.gov/pubmed/26542177 +Pubmed +DOI
• Pérez-Valderrama B, Arranz Arija JA, Rodríguez Sánchez A, Pinto Marín A, Borrega García P, Castellano Gaunas DE, Rubio Romero G, Maximiano Alonso C, Villa Guzmán JC, Puertas Álvarez JL, Chirivella González I, Méndez Vidal MJ, Juan Fita MJ, León-Mateos L, Lázaro Quintela M, García Domínguez R, Jurado García JM, Vélez de Mendizábal E, Lambea Sorrosal JJ, García Carbonero I, González del Alba A, Suárez Rodríguez C, Jiménez Gallego P, Meana García JA, García Marrero RD, Gajate Borau P, Santander Lobera C, Molins Palau C, López Brea M, Fernández Parra EM, Reig Torras O, Basterretxea Badiola L, Vázquez Estévez S, González Larriba JL. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study. Ann Oncol Off J Eur Soc Med Oncol. 2016 Apr;27(4):706-11. PMID: 26658889. IF2016: 11.855; D1. http://www.ncbi.nlm.nih.gov/pubmed/26658889 +Pubmed +DOI
• Sánchez-Ares M, Cameselle-Teijeiro JM, Vázquez-Estévez S, Lázaro-Quintela M, Vázquez-Boquete Á, Afonso-Afonso FJ, Casal-Rubio J, González-Pineiro AL, Rico-Rodríguez Y, Fírvida-Pérez JL, Ruíz-Banobre J, Couso E, Santomé L, Pérez-Becerra R, García-Campelo R, Amenedo M, Azpitarte-Raposeiras C, Antúnez J, Abdulkader I. Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia). Oncol Lett. 2016 Aug;12(2):1403-7. PMID: 27446444. IF2016: 1.390; Q4. http://www.ncbi.nlm.nih.gov/pubmed/27446444 +Pubmed +DOI
• Vázquez S, Casal J, Afonso Afonso FJ, Fírvida JL, Santomé L, Barón F, Lázaro M, Pena C, Amenedo M, Abdulkader I, González-Arenas C, Fachal L, Vega A. EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10). Cancer Manag Res. 2016 Feb;8:11-20. PMID: 26893581. IF2016: 3.851; Q2. http://www.ncbi.nlm.nih.gov/pubmed/26893581 +Pubmed +DOI

Capítulos de libro

• Lorenzo-Lorenzo I. TNE torácicos: pulmón y timo. Guía práctica de diagnóstico, tratamiento y seguimiento de tumores neuroendocrinos. Versión 3. EdikaMed S.L; 2016. p. 51-70. ISBN: 978-84-7877-892-8. +Info http://www.getne.org/LinkClick.aspx?fileticket=lxEtmyHm2NI%3D

Guías de Práctica Clínica

• Lázaro-Quintela M, Vázquez-Éstevez S, León-Mateos L, Grande-Pulido E, Antón-Aparicio L. Tratado de tumores raros. Grupo GETHI; 2016. ISBN: 978-84-697-0596-4. +Info http://www.tratadodetumoresraros.com/

Artículos Científicos

• Anido Herranz U, Fernández Calvo O, Afonso Afonso FJ, Rodríguez Martínez de Llano S, Lázaro Quintela M, León Mateos L, Vázquez Estévez S, Antón Aparicio LM. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Expert Rev Anticancer Ther. 2015 Mar;15(3):339-48. PMID: 25555355. IF2015: 2.094; Q3. http://www.ncbi.nlm.nih.gov/pubmed/25555355 +Pubmed +DOI
• Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, Ramchandani A, Martínez J, Hernando Cubero J, Espinosa J, Martínez de Castro E, Ghanem I, Beato C, Blasco A, Garrido M, Bonilla Y, Mondéjar R, Arcusa Lanza MÁ, Aragón Manrique I, Manzano A, Sevillano E, Castanón E, Cardona M, Gallardo Martín E, Pérez Armillas Q, Sánchez Lasheras F, Ayala de la Pena F. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015 Feb;33(5):465-71. PMID: 25559804. IF2015: 20.982; D1. http://www.ncbi.nlm.nih.gov/pubmed/25559804 +Pubmed +DOI
• Goday A, Barneto I, García-Almeida JM, Blasco A, Lecube A, Grávalos C, Martínez de Icaya P, de las Penas R, Monereo S, Vázquez L, Palacio JE, Pérez-Segura P. Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015 Oct;17(10):763-71. PMID: 26036853. http://www.ncbi.nlm.nih.gov/pubmed/26036853 +Pubmed +DOI
• Iglesias Rey L, Fernández Pérez I, Barbagelata López C, Rivera Gallego A. [Venous thrombosis associated with central venous catheter use in patients with cancer]. Med Clin (Barc). 2015 Jan;144 Suppl(Suppl 1):41-3. PMID: 25771092. IF2015: 1.267; Q2. http://www.ncbi.nlm.nih.gov/pubmed/25771092 +Pubmed +DOI
• Quintela ML, Mateos LL, Estévez SV, Calvo OF, Herranz UA, Afonso FJA, Santomé L, Aparicio LA. Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor. Cancer Treat Rev. 2015 Mar;41(3):247-53. PMID: 25638257. IF2015: 7.983; D1. http://www.ncbi.nlm.nih.gov/pubmed/25638257 +Pubmed +DOI
• Quintero-Aldana G, Jorge M, Grande C, Salgado-Fernández M, Gallardo E, Varela S, López C, Villanueva MJ, Fernández A, Alvarez E, González P, Castellanos J, Casal J, López R, Campos Balea B. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer. Cancer Chemother Pharmacol. 2015 Oct;76(4):731-7. PMID: 26242221. IF2015: 2.824; Q2. http://www.ncbi.nlm.nih.gov/pubmed/26242221 +Pubmed +DOI
• Salvador J, Manso L, de la Haba J, Jaen A, Ciruelos E, de Villena MC, Gil M, Murias A, Galan A, Jara C, Bayo J, Baena JM, Casal J, Mel JR, Blancas I, Sanchez Rvira P. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clin Transl Oncol. 2015 Feb;17(2):160-6. PMID: 25119930. IF2015: 2.075; Q3. http://www.ncbi.nlm.nih.gov/pubmed/25119930 +Pubmed +DOI
• Vázquez S, Villanueva M, Fírvida J, Campos B, Lázaro M, Huidobro G, Areses M del, Fernández N, Covela M, Casal J. Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors. J Anal Oncol. 2015 Sep;4(3):94-101. DOI: 10.6000/1927-7229.2015.04.03.1. IF2015: N/A. http://www.lifescienceglobal.com/journals/journal-of-analytical-oncology/volume-4-number-3/89-abstract/jao/1769-abstract-erlotinib-as-second-line-therapy-for-patients-with-advanced-non-small-cell-lung-cancer-and-wild-type-egfr-tumors +DOI

Capítulos de libro

• Areizaga LM, Carrasco JA, de las Penas R, Sala MÁ. Tumores mesenquimales de comportamiento localmente agresivo. In: Martín Brogo J, Valverde C, Cubedo R, Cruz J (eds.). Tratado de sarcomas de partes blandas. Madrid: NPG editorial; 2015. ISBN: 978-84-940238-4-2. +Info http://www.mcu.es/webISBN/tituloDetalle.do?sidTitul=2189870&action=busquedaInicial&noValidating=true&POS=0&MAX=50&TOTAL=0&prev_layout=busquedaisbn&layout=busquedaisbn&language=es
• León L, Antón-Aparicio LM, Esteban-González E, Lázaro-Quintela M, Vázquez-Estévez S. Side Effects of Targeted Therapy. In: Bukowski RM, Figlin RA (eds.). Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Springer New York; 2015. p. 377-416. ISBN: 9781493916221; 9781493916214. +Info https://www.scopus.com/inward/record.uri?eid=2-s2.0-84944617211&doi=10.1007%2F978-1-4939-1622-1&partnerID=40&md5=bf8e2dbe634de533fe761b000ee5ba2d +DOI
• Vázquez ML, Gallardo Martín E, Pena C, Lorenzo I, Constenla M. Capítulo 38. Cáncer Colorrectal no Polipósico. In: Pazos A, Ulla J (eds.). Abordaje multidisciplinar de cáncer colorrectal. 1st ed. Santiago de Compostela: Andavira Editora S.L.; 2015. p. 611-32. ISBN: 978-84-8408-795-3. +Info http://www.andavira.com/ebooks/cancer_colorrectal/files/assets/basic-html/page-16.html#

Artículos Científicos

• Casal Rubio J, Fírvida-Pérez JL, Lázaro-Quintela M, Barón-Duarte FJ, Alonso-Jáudenes G, Santomé L, Afonso-Afonso FJ, Amenedo M, Huidobro G, Campos-Balea B, López-Vázquez MD, Vázquez S. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study. Cancer Chemother Pharmacol. 2014 Mar;73(3):451-7. PMID: 24352251. IF2014: 2.769; Q3. http://www.ncbi.nlm.nih.gov/pubmed/24352251 +Pubmed +DOI
• Fernández O, Afonso J, Vázquez S, Campos B, Lázaro M, León L, Antón Aparicio LM. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel. Anticancer Drugs. 2014 Mar;25(3):237-43. PMID: 24217332. IF: 1.784; Q4. http://www.ncbi.nlm.nih.gov/pubmed/24217332 +Pubmed +DOI
• Juan O, Sánchez-Hernández A, Vázquez S, Casal J, Firvida JL, Aparisi F, Munoz J, García-Sánchez J, Gironés R, Lázaro M, Giner V. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study. Anticancer Res. 2014 Apr;34(4):1959-66. PMID: 24692732. IF: 1.826; Q4. http://www.ncbi.nlm.nih.gov/pubmed/24692732 +Pubmed
• Vazquez S, Lazaro M, Luis Firvida J. Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile. Anticancer Drugs. 2014 Apr;25(4):368-74. PMID: 24384805. IF: 1.784; Q4. http://apps.isiknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=4&SID=S2uGjT3vB4ldo5YTNQB&page=1&doc=7 +Pubmed +DOI